BiVictriX adds two new drug development programmes

The AIM-traded firm said BVX002 and BVX003 target novel cancer-specific twin antigen fingerprints, incorporating its proprietary ‘Bi-Cygni’ technology, alongside the established and validated antibody drug conjugate (ADC) mechanism of action, to form the next-generation of Bi-Cygni ADCs with superior cancer selectivity.

It said the programmes enabled the targeting of several haematological and solid tumour cancer indications, and would be developed alongside BiVictriX's lead asset, ‘BVX001’, which has a lead indication in acute myeloid leukaemia (AML).

The board said the pipeline expansion demonstrated the “broad utility” of the Bi-Cygni approach across a wide range of solid tumour and haematological cancer types, which constituted areas of “significant” unmet medical need, and further highlighted the potential expansion of the platform in novel areas of immuno-oncology.

It said the pipeline expansion followed the company's recent filing of four new patent applications to further strengthen its growing intellectual property portfolio in the UK and internationally.

The patents, which would form part of a new patent family for BiVictriX, related to several novel cancer-specific antigen pairs - or ‘fingerprints’ - across a range of oncology indications, which had been identified by the company.

“This is an exciting announcement for the company,” said chief executive officer Tiffany Thorn.

“The expansion of our current therapeutic pipeline to include two additional programmes moving into the early stages of development is a significant milestone and enables BiVictriX to demonstrate the broad utility of its promising new approach to cancer therapeutic development across a wide range of difficult-to-treat cancers, including both solid tumour and haematological indications that currently represent areas of urgent unmet medical need.

“We are focused on working to fast-track the development of these two new programmes alongside our lead asset, BVX001, to reach early preclinical proof of concept in the short to medium term.”

At 1520 GMT, shares in BiVictriX Therapeutics were flat at 22.5p.